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Abstract To investigate the role of charged intramembrane res- 
idues in the function of the rabbit Na+lglucose cotransporter 
(rbSGLT1) we substituted arginine-427 (R427) by alanine in the 
putative domain M9 SGLT1. This residue is conserved in all the 
members of the SGLT1 family. The mutant protein (R427A) was 
expressed in Xenopus oocytes and, although Western blot analy- 
sis revealed that it was produced in amounts comparable to wild- 
type, no function was measured. Freeze-fracture analysis showed 
that R427A SGLT1 was not in the plasma membrane while im- 
munocytochemical experiments localized the transporter to just 
beneath it. These results indicate that arginine-427 plays a critical 
role in SGLT1 trafficking to the plasma membrane. 
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1. Introduction 
An approach to structure/function relations of membrane 
ploteins is site-directed mutagenesis, especially of conserved 
charged residues in transmembrane domains because they are 
th,~ught o play an important role in protein function. For 
example, mutation of aspartic acid-176 to alanine (D176A) in 
tr~msmembrane domain M4 of the rabbit Na+/glucose cotrans- 
pc, rter (rbSGLT1) alters the kinetics of charge transfer without 
changing the steady-state kinetics [1]. The interpretation of 
su=h experiments can be more complex because mutations can 
aher translation, processing and trafficking from the endoplas- 
m~c reticulum to the plasma membrane. In this study, we have 
cl~anged arginine at position 427 of rbSGLTI to alanine, ex- 
p~ essed this protein in Xenopus oocytes and used a combination 
oI techniques to address such questions. Although the protein 
wts produced, no functional expression was obtained. This 
st~ggested a defect in either protein trafficking or in the function 
oI the cotransporter. We then used freeze-fracture and im- 
mmocytochemistry methods to localize the mutated protein 
al~d found that R427A SGLT1 was not in the plasma mem- 
b~ ane but it was just beneath it. We conclude that the substitu- 
ti,,n of a charged residue in the conserved transmembrane do- 
main M9 of rbSGLT1 by a neutral amino acid (R427A) blocks 
tl~ delivery of the transporter to the plasma membrane. 
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2. Material and methods 
2.1. Site-directed mutagenesis and cRNA synthesis 
The plasmid carrying the cDNA sequence for rbSGLT1 [1] was used 
as template to perform oligonucleotide-directed mutagenesis [2]. The 
sequence of the synthetic oligonucleotide used to introduce the R427A 
mutation in its 5'~3' direction was: CAGGAACAGCATGAACAAC- 
GCTCC TGCGATCATGA (mutated nucleotides in bold letters). The 
mutated fragment was ligated into the KpnIIHincI1 sites of the wild-type 
vector and completely sequenced (Sequenase v rsion 2.0, U.S.B., Cleve- 
land, OH) to confirm the fidelity of the mutation. The recombinant 
plasmid then was linearized with EcoRI and in vitro transcription 
performed with a MEGAscript transcription kit from Ambion (Austin, 
TX). 
2.2. Oocyte preparation and functional assays 
Xenopus laevis oocytes were isolated, injected with cRNA coding for 
wild-type (WT) or R427A rbSGLTI and 50 ,uM [t4C]-c~-methyl-D-glu- 
coside (c~MDG) uptake was measured 3-7 days later [3]. SGLT1 mem- 
brane currents were measured using the two-microelectrode voltage 
clamp method [3]. 
2.3. Western blot analysis 
Two oocytes expressing either wild-type or mutant rbSGLT1 were 
homogenized in 100 mM NaC1, 20 mM Tris-HC1, 1% Elugent (Calbio- 
chem, La Jolla, CA), pH 7.5 (15/~1 per oocyte) and centrifuged to 
remove the insoluble yolk and lipids. Protein samples were mixed with 
sample buffer, and a volume equivalent to 1/3 of oocyte was run on a 
12% SDS-PAGE mini-gel and transferred to nitrocellulose membranes. 
Rabbit brush border membrane vesicles (BBMV) and non-injected (NI) 
oocytes were used as controls. SGLT1 was detected using polyclonal 
antibody raised to residues 602 613 of rb SGLT1 [4] at a dilution of 
1:1,000. Affinity-purified goat anti-rabbit IgG peroxidase conjugate 
(Calbiochem, La Jolla, CA) at 1 : 12,000 dilution was used as secondary 
antibody. Immunoreactive proteins were visualized by chemilumines- 
cence (Renaissance TM Dupont, Boston, MA). 
2.4. Freeze-fi'acture and immunocytochemistry 
Oocytes were fixed and freeze-fractured as previously described [5]. 
Oocytes expressing WT and R427A mutant proteins, non-injected 
oocytes and rat jejunum were fixed in 3% formaldehyde-PBS at 22°C 
for 2 h, rinsed 3 x 10 min with PBS and stored in 20% sucrose-PBS 
overnight at 4°C. Oocytes and tissue were embedded in OCT com- 
pound (Miles Inc., Elkhart, IN), rapidly frozen in dry ice and stored 
at -80°C. Cryostat sections of 6-8/zm thickness were cut, mounted on 
slides, dried and stored at -20°C. Sections were blocked for 10 min with 
5% of normal goat serum-PBS and incubated for 1 h in a 1 : 100 dilution 
of an antibody raised to residues 564~575 of rbSGLT1 [6]. After wash- 
ing with PBS 3 x 10 min, sections were covered with 10 ¢tg/ml rhodam- 
ine-labeled affinity-purified goat anti-rabbit IgG (Jackson Immuno Re- 
search Laboratories Inc., West Grove, PA) for 40 mira and then washed 
with PBS 3 × 10 min. Intestinal sections were stained for nuclei with 
2 /lg/ml DAPI (4',6-diamidino-2-phenylindole ihydrochloride, Re- 
search Organics Inc., Cleveland, OH). As controls, rat jejunum and 
oocytes expressing wild-type SGLT1 were incubated either in normal 
rabbit serum or PBS in the absence of primary antibody, and then with 
secondary antibody. Specimens were mounted in 200 mM DABCO 
(1,4-diazabicyclo[2.2.2]octane, Sigma Chemical Co., St Louis, MO), 
90% glycerol, 10% PBS to retard fading of the fluorescence and exam- 
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ined with a fluorescence microscope. Experiments with rat jejunum 
were carried out to confirm that the antibody recognized SGLT1 in the 
brush border membrane [6]. 
The sections were imaged by line averaging with a Zeiss LMS- 10 laser 
confocal microscope (Carl Zeiss Inc., San Leandro, CA). Fluorescence 
was excited with the 567 nm band of an argon/krypton laser and the 
emission bandpass filter was 580-645 nm. The optical path included a
X63 oil Plan Neofluar lens (numerical perture 1.25). Contrast of the 
captured images was enhanced using Lynx 5.1 imaging software (Ap- 
plied Imaging Co., Santa Clara, CA). 
3. Results 
The uptake of 50 #M [14C]0~MDG by the WT cRNA injected 
oocytes was about 100-fold higher than the uptake of R427A 
mutant (384 + 36 and 3.7 + 0.3 pmol/oocyte per h), which was not 
significantly different from non-injected oocytes (4.6 + 0.4 pmol/ 
oocyte per h). These results indicate that the R427A mutant 
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Fig. 1. Steady-state current-voltage (1/V) and charge-voltage (Q/V) 
relationship of WT and R427A rbSGLT1. (A) Current-voltage r la- 
tionship of Na ÷ inward current induced by 5 mM ~MDG by WT and 
R427A SGLT1 proteins. (B) Voltage dependence of the charge move- 
ment. Q was obtained by integration ofthe current transients recorded 
in the absence of sugar at each membrane potential. The curves are 
drawn according to the Boltzman relation [7] and the symbols corre- 
spond to experimental data. The results are presented for single oocytes 
6 days after injection of cRNA. Similar esults were obtained in three 
different batches of oocytes. 
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Fig. 2. Western blot analysis of wild-type and R427A mutant rbSGLT 1 
expressed in oocytes. Proteins were extracted from two oocytes 7 days 
after injection with WT or R427A mutant cRNA. The oocytes were 
from the same batch of oocytes used for Fig. 4. Lane 1, rabbit intestinal 
brush border membrane vesicles (BBMV) showing that the native gly- 
cosylated SGLT1 protein runs as a ~ 70 kDa band. Lane 2, non-injected 
oocyte (NI). Lane 3, wild-type rbSGLT1 expressed into oocytes which 
runs as two bands, one of the same size as the native intestinal brush 
border protein (lane 1) and a second, smaller band of ~ 60 kDa. Lane 4, 
R427A mutant which shows the same bands, at comparable intensities, 
as wild type. 
does not transport ~MDG or, if it does, with greatly reduced 
affinity. We tested this second possibility using electrophysiol- 
ogical methods. Fig. 1A shows the steady-state current-voltage 
relationship of the WT and R427A SGLT1 generated by 5 mM 
~MDG. At -150 mV membrane potential, WT produced a 
current of-2,230 nA whereas R427A did not induce an inward 
current at any membrane potential. In the absence of sugar, 
WT SGLT 1 exhibits characteristic transient currents after volt- 
age steps in the membrane potential. These currents are due to 
SGLT 1 charge movement (Q), and Qmax is directly proportional 
to the number of transporters in the membrane [5,7]. Fig. 1B 
shows the charge movement of WT and R427A SGLT1 as a 
function of voltage. At each membrane potential (10, Q was 
determined as the integral of the transient currents (symbols) 
and the Q/V current was fitted to the Boltzmann equation [7]. 
Qmax for WT was 97 nC but for R427A was less than 7 nC. 
The lack of functional expression of R427A SGLT1 could be 
due to defects in cRNA translation, trafficking of the synthe- 
sized transporter to the plasma membrane, or activity of the 
mutant protein. Western blot anlaysis was carried out to re- 
solve if the cRNA was translated. Fig. 2 shows both WT and 
mutant proteins as two bands, one of the same size as BBMV 
(70 kDa) and a band of ~60 kDa that corresponds to the core- 
glycosylated protein. 
The freeze-fracture method was then used to determine 
whether R427A protein was inserted into the plasma mem- 
brane. Fig. 3A shows the P face of an R427A cRNA injected 
oocyte where 7 nm diameter particles are found at a density of 
190 + 70 per tim 2. This is the same density as in water injected 
oocytes (212 + 48 per/.tm 2) and corresponds to endogenous 
membrane proteins [5]. In WT cRNA injected oocytes the den- 
sity of particles increased to -5,000 per/./m 2 (Fig. 3B) levels 
similar to that reported earlier for SGLTI [5]. 
Immunocytochemistry experiments were performed to local- 
ize WT and mutant SGLT 1 in the oocyte. Fig. 4 shows confocal 
images of WT (A) and R427A (B) SGLT1 expressing oocytes 
in which the background intracellular fluorescence (Fig. 4C and 
D) has been subtracted to highlight he differences in localiza- 
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Fi~. 3. The P fracture faces of plasma membranes of oocyte injected 
wi~h R427A or wild-type cRNA. R427A (A) injected oocytes how 
7 ~tm diameter particles at a density of 190+70 per/lm 2, whereas in 
wild-type injected oocytes (B) the density of those particles increases to 
5J~00 per/.tm:. There was no change in the density of E-face particles 
[5] Magnification: x 85,000. 
ti~ n of the two proteins. WT is restricted to the plasma mem- 
brine whereas R427A SGLT1 immunoreactivity appears just 
beneath it. No immunoreactivity was observed in either non- 
in ected oocytes or oocytes not exposed to primary antibody. 
4. Discussion 
Site-directed mutagenesis is a popular tool to study the struc- 
tu r'e and function of cloned membrane proteins uch as trans- 
p~ rters, channels and receptors. However, as this study demon- 
st~ ates, there is a serious limitation of this approach in expres- 
si,,n systems when the mutant proteins are not inserted prop- 
er y into the plasma membrane. We have found that simply 
changing a single residue in rbSGLT1 (R427A) dramatically 
alters the traffÉcking of the protein to the plasma membrane. 
Although there were comparable levels of WT and mutant 
proteins in the cell (Fig. 2), both sugar uptake and sugar- 
dependent currents for R427A SGLT1 were not significantly 
above control oocyte values (Fig. 1A). Charge movement meas- 
urements (Fig. IB) and freeze-fracture electron micrographs of 
the plasma membrane (Fig. 3) further demonstrated that the 
level of the mutant protein in the plasma membrane was less 
than 7% of the WT. We therefore conclude that there was no 
functional expression of R427A SGLT1 in oocytes imply be- 
cause the protein was not inserted into the plasma membrane. 
In oocytes, as in other eukaryotes, membrane proteins are 
translated and assembled by the ribosome/endoplasmic reticu- 
lum (ER) complex, core glycosylated in the ER, and passed 
along the Golgi apparatus to the trans-Golgi where they are 
fully glycosylated. Then, plasma membrane proteins bud off 
from the Golgi apparatus in vesicles where they are directed to 
the plasma membrane. Western blot analysis of the mutant 
SGLT1 protein provides a clue about the site of the defect. The 
amounts of protein expression were similar for both mutant 
and wild-type transporters, aswere the levels of core and com- 
plex glycosylation (Fig. 2). This suggests that the translation, 
insertion into the ER, folding, and trafficking of the R427A 
mutant SGLT1 to the trans-Golgi apparatus are normal. The 
immunocytochemical studies (Fig. 4) show that the mutant 
protein is found in a punctate pattern just below the plasma 
membrane. This, together with the glycosylation pattern and 
preliminary cell fractionation experiments (Hirayama, unpub- 
lished results), suggests that the R427A mutation blocks dock- 
ing of the transport vesicle with the plasma membrane 
How general is this effect of a mutation on trafficking?. A
clue comes from our recent study of patients uffering from 
glucose-galactose malabsorption [8,9]. In 29 kindreds 18 differ- 
ent missense mutations were found in the SGLTI gene that 
Fig. 4. Confocal fluorescence images (1 mm) of WT and R427A SGLT1 expressing oocytes. Panel A shows WT localized in the plasma membrane 
ol the oocyte and panel B shows R427A localized beneath the membrane. Magnification: × 62. Panels C and D are the light microscopic semithin 
section (6 8 Hm) from which the confocal images were taken. The oocytes were from the same batch as Fig. 2. Magnification: x 23. 
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account for the defect in sugar transport. Using the oocyte 
expression system, the missense mutations cause a severe im- 
pairment of sugar transport by SGLT1, and the defect appears 
to be mainly due to a trafficking problem: little or no charge 
transfer was observed with several mutants (D28N, A304V, 
R499H), and no D28N transporter was found in the plasma 
membrane using the freeze-fracture electron microscopic tech- 
nique employed here (unpublished observations) even though 
Western blots showed normal evels of SGLT1 protein in the 
cells. In all of the GGM missense mutations and the R427A 
mutation studied here the mutated amino acid is highly con- 
served among the 12 members of the SGLT1 gene family [9]. 
Our results uggest that the trafficking and targeting machinery 
in oocytes interacts closely with the cotransporter protein in the 
transport vesicle, and that these interactions can be disrupted 
by changes in one out of 664 residues in the cotransporter 
sequence, including fairly conservative changes in amino acids, 
e.g. A304V and A388V. 
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